1,500 Elevance Health, Inc. $ELV Shares Sold by Larry Mathis Financial Planning LLC

Larry Mathis Financial Planning LLC reduced its position in Elevance Health, Inc. (NYSE:ELV) by 54.9% in the third quarter, Holdings Channel.com reports. The fund owned 1,233 shares of the company’s stock after selling 1,500 shares during the quarter. Larry Mathis Financial Planning LLC’s holdings in Elevance Health were worth $479,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ELV. Activest Wealth Management lifted its stake in Elevance Health by 146.2% in the 3rd quarter. Activest Wealth Management now owns 64 shares of the company’s stock worth $25,000 after purchasing an additional 38 shares in the last quarter. Kilter Group LLC bought a new position in Elevance Health in the 2nd quarter valued at $28,000. WealthCollab LLC grew its position in shares of Elevance Health by 42.2% during the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after purchasing an additional 27 shares in the last quarter. Elevation Wealth Partners LLC grew its position in shares of Elevance Health by 600.0% during the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock valued at $41,000 after purchasing an additional 90 shares in the last quarter. Finally, Tacita Capital Inc purchased a new position in shares of Elevance Health during the 2nd quarter valued at $44,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Insider Buying and Selling

In related news, CFO Mark Kaye sold 10,584 shares of the stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. This represents a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Elevance Health Price Performance

ELV stock opened at $431.38 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69. The stock has a market cap of $93.20 billion, a PE ratio of 18.40, a P/E/G ratio of 2.10 and a beta of 0.70. The firm has a 50 day simple moving average of $408.19 and a two-hundred day simple moving average of $371.09.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. The firm had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business’s quarterly revenue was up .7% on a year-over-year basis. During the same quarter last year, the company posted $6.03 EPS. On average, analysts predict that Elevance Health, Inc. will post 29.11 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s payout ratio is 29.34%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Leerink Partners upped their price target on shares of Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Raymond James Financial set a $450.00 price objective on Elevance Health in a research note on Tuesday, July 7th. Sanford C. Bernstein set a $488.00 target price on Elevance Health in a research report on Thursday, July 16th. UBS Group upped their target price on Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wells Fargo & Company decreased their target price on Elevance Health from $492.00 to $473.00 and set an “overweight” rating on the stock in a research note on Thursday, July 16th. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and a consensus target price of $455.57.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.